Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Akero Fiscal Q3 2021 Earnings Report - CapyFin

Akero

AKRO · NASDAQ🇺🇸

View Company

Overview Earnings

Dividends Seasonality Metrics

Q3 2025 +0.20%Q2 2025 +0.08%Q1 2025 +4.30%Q4 2024 +2.87%Q3 2024 -5.25%Q2 2024 -2.97%Q1 2024 -0.87%Q4 2023 +2.13%Q3 2023 +5.30%Q2 2023 +6.16%Q1 2023 +0.15%Q4 2022 -4.10%Q3 2022 -6.81%Q2 2022 +18.38%Q1 2022 -11.39%Q4 2021 -1.94%Q3 2021 +4.56%Q2 2021 +0.97%Q1 2021 +2.58%Q4 2020 -1.06%Q3 2020 -3.02%Q2 2020 -0.92%Q1 2020 +2.83%Q4 2019 -20.89%Q3 2019 -3.77%Q2 2019 +1.27%Q1 2019 Q4 2018 Q3 2018 Q2 2018 Q1 2018 Q4 2017

Nov 12, 2021

•

Sep 30, 2021

Akero Q3 2021 Earnings Report

Akero Therapeutics reported financial results for the third quarter of 2021.

Key Takeaways

Akero Therapeutics reported third quarter financial results with focus on advancing efruxifermin (EFX) through Phase 2b clinical trials for NASH treatment.

Focused on completing two Phase 2b clinical trials.

Diligently working with regulators to bring efruxifermin (EFX) to market.

Received Fast Track designation from the FDA.

EFX is being evaluated in the HARMONY and SYMMETRY studies.

EPS

-$0.7

Previous year: -$0.63